| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
5
5
4
4
|
|
Zacks Investment Research
3
(Hold)
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
A+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 1.17 | 1.17 |
| Stocks | 75.75 | 75.75 |
| Bonds | 0.0 | 0.0 |
| Other | 0.83 | 0.83 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 21.31 | 21.31 |
| Convertible | 0.94 | 0.94 |
| Preferred | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 05.31.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Gilead Sciences Inc | GILD | 44.64 | 4.52 |
| Celgene Corporation | CELG | 54.06 | 4.22 |
| Aetna Inc | AET | 29.73 | 3.6 |
| Express Scripts | ESRX | 16.43 | 3.37 |
| Medivation, Inc. | MDVN | -4.79 | 2.49 |
| Valeant Pharmaceuticals International Inc | VRX | 47.58 | 2.31 |
| Omnicare Inc | OCR | 28.95 | 2.08 |
| AbbVie Inc | ABBV | 29.27 | 2.0 |
| Shire PLC ADR | SHPG | 7.79 | 1.96 |
| Roche Holding AG | RHHVF | 21.67 | 1.91 |
